ATHE
HEALTHCAREAlterity Therapeutics Ltd
$4.52-0.01 (-0.22%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ATHE Today?
No stock-specific AI insight has been generated for ATHE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.66$7.00
$4.52
Fundamentals
Market Cap$85M
P/E Ratio—
EPS$-0.58
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-2.2%
Debt / Equity—
Trading
Volume15K
Avg Volume (10D)—
Shares Outstanding18.1M
ATHE News
20 articles- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026Yahoo Finance·May 7, 2026
- Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate UpdateYahoo Finance·Apr 30, 2026
- Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System AtrophyYahoo Finance·Apr 27, 2026
- Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of NeurologyYahoo Finance·Apr 22, 2026
- Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of DirectorsYahoo Finance·Apr 17, 2026
- Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual MeetingYahoo Finance·Apr 16, 2026
- Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System AtrophyYahoo Finance·Apr 15, 2026
- Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 ProgramYahoo Finance·Mar 30, 2026
- Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons SummitYahoo Finance·Mar 9, 2026
- Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical AdvisorYahoo Finance·Mar 4, 2026
- Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying TreatmentsYahoo Finance·Mar 2, 2026
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate UpdateYahoo Finance·Jan 30, 2026
- Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026Yahoo Finance·Jan 21, 2026
- Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual ConferenceYahoo Finance·Nov 12, 2025
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous SystemYahoo Finance·Nov 10, 2025
- Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow ReportYahoo Finance·Oct 31, 2025
- Alterity Therapeutics Limited's (ASX:ATH) Path To ProfitabilityYahoo Finance·Oct 11, 2025
- Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 StudyYahoo Finance·Oct 9, 2025
- Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement DisordersYahoo Finance·Oct 9, 2025
- Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement DisordersYahoo Finance·Oct 2, 2025
All 20 articles loaded
Price Data
Open$4.69
Previous Close$4.53
Day High$4.69
Day Low$4.52
52 Week High$7.00
52 Week Low$2.66
52-Week Range
$2.66$7.00
$4.52
Fundamentals
Market Cap$85M
P/E Ratio—
EPS$-0.58
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-2.2%
Debt / Equity—
Trading
Volume15K
Avg Volume (10D)—
Shares Outstanding18.1M
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—